PDC*line Pharma
PrivateLast Round
Grant
Jan 17, 2024
Total Funding Raised
$26.98M
Company Overview
PDC*line Pharma operates in Healthcare & Life Sciences and is based in Liège. Its latest recorded funding round was a Grant round in January 2024.
PDC*line Pharma is a biotechnology company that develops a class of potent and off-the-shelf therapeutic cancer vaccines based on a proprietary cell line of Plasmacytoid Dendritic Cells (PDC*line).
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PDC*line Pharma Comparables
Compare PDC*line Pharma with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| OxVax Ltd. | 84% | |
| IO Biotech | 78% | |
| Mendus AB | 76% |
For institutional investors. Book with your work email.
PDC*line Pharma Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Grant | Jan 17, 2024 | ||||
| Series B Extension | Dec 6, 2021 | ||||
| Debt | Jan 22, 2020 | ||||
| Debt | Dec 6, 2016 |
For institutional investors. Book with your work email.
PDC*line Pharma Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Federal Holding and Investment Company | Debt, Series B Extension |
| Korea Investment Partners | Debt, Series B Extension |
| Noshaq | Debt, Series B Extension |
| Société Régionale d'Investissement de Wallonie | Debt, Series B Extension |
| Wallonie Entreprendre | Grant |
| Brain Asset Management Co.,Ltd. | Series B Extension |
| Korea Investment Partners | Debt |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jan 17, 2024
$5.1M grant received from BioWin and government entities.
- Dec 6, 2021
$14M round led by Korea Investment Partners.
For institutional investors. Book with your work email.
PDC*line Pharma Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PDC*line Pharma's valuation, stock price, and market status.
Is PDC*line Pharma a public or private company?
PDC*line Pharma is a private company.
What is the current stock price of PDC*line Pharma?
PDC*line Pharma is a private company, so its shares have no public market price. Caplight tracks PDC*line Pharma's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PDC*line Pharma worth (valuation)?
Valuation information for PDC*line Pharma is not publicly available.
Can I buy PDC*line Pharma stock?
PDC*line Pharma shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PDC*line Pharma's last funding round?
PDC*line Pharma's most recent funding round was Grant on January 17, 2024.
Who are the main investors in PDC*line Pharma?
Key investors in PDC*line Pharma include Korea Investment Partners, Korea Investment Partners.
Will PDC*line Pharma IPO soon?
No public IPO plans have been announced for PDC*line Pharma.
How can I track PDC*line Pharma secondary market activity?
Caplight tracks bids, offers, and trades in PDC*line Pharma's shares on secondary markets.